Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299726 | PMC |
| http://dx.doi.org/10.3389/fphar.2023.1234219 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between internet use and primary headache severity among Hungarian university students: a cross-sectional study.
Front Public Health
December 2024
Department of Ophtalmology, Medical School, University of Pécs, Pécs, Hungary.
Background: Recent studies suggest that increased digital technology usage could be a factor in the rising occurrence and severity of headache episodes. The purpose of this cross-sectional study was to determine whether the severity of primary headaches (migraine and tension-type headache) is associated with problematic internet use taking many covariates into account.
Methods: We conducted an online cross-sectional survey using a quantitative, descriptive questionnaire, targeting university students enrolled in correspondence courses, aged 18 to 65.
Mandatory surveillance of bacteremia conducted by automated monitoring.
Front Public Health
December 2024
Department of Data Integration and Analysis, Statens Serum Institut, Copenhagen, Denmark.
Except for a few countries, comprehensive all-cause surveillance for bacteremia is not part of mandatory routine public health surveillance. We argue that time has come to include automated surveillance for bacteremia in the national surveillance systems, and explore diverse approaches and challenges in establishing bacteremia monitoring. Assessed against proposed criteria, surveillance for bacteremia should be given high priority.
View Article and Find Full Text PDFPiecing together the narrative of #longcovid: an unsupervised deep learning of 1,354,889 X (formerly Twitter) posts from 2020 to 2023.
Front Public Health
December 2024
Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
Objective: To characterize the public conversations around long COVID, as expressed through X (formerly Twitter) posts from May 2020 to April 2023.
Methods: Using X as the data source, we extracted tweets containing #long-covid, #long_covid, or "long covid," posted from May 2020 to April 2023. We then conducted an unsupervised deep learning analysis using Bidirectional Encoder Representations from Transformers (BERT).
Immunoproteasome inhibition reduces donor specific antibody production and cardiac allograft vasculopathy in a mouse heart transplantation model.
Front Transplant
December 2024
Duke Transplant Center, Duke University School of Medicine, Durham, NC, United States.
Objective: Cardiac Allograft Vasculopathy (CAV), a process of vascular damage accelerated by antibody-mediated rejection (AMR), is one of the leading causes of cardiac transplant failure. Proteasome inhibitors (PIs) are utilized to treat AMR, however PI-associated toxicity limits their therapeutic utility. Novel immunoproteasome inhibitors (IPIs) have higher specificity for immune cells and have not been investigated for AMR in cardiac transplant patients.
View Article and Find Full Text PDFImmunological characterization of pleural effusions in pediatric patients.
Front Immunol
December 2024
Department of General Pediatrics and Neonatology, Saarland University, Campus Homburg, Homburg, Germany.
Background: The pleural cavity represents a unique immunological compartment that can mount inflammatory reactions during infections, after surgery and in chronic immunological diseases. The connection between systemic immune reactions in the blood and local immune reactions in pleural effusions remains unclear. This study provides the first comprehensive immunological characterization of paired blood and pleural effusion samples, utilizing combined cell and cytokine analyses in pediatric patients undergoing cardiac surgery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!